中国基因组学公司诺禾致源起诉美国国防部：挑战「中国军事企业」列名
华盛顿——中国基因组学公司诺禾致源（Novogene，上海证券交易所科创板代码：688315）及其美国子公司11月3日向位于华盛顿的美国哥伦比亚特区联邦地区法院起诉美国国防部，挑战五角大楼今年6月把该公司列入「中国军事企业」清单的决定，要求撤销列名。
诉状称，国防部列名时证据不足、未事先通知公司、未给予回应机会，违反《行政程序法》与美国宪法第五修正案的正当程序保障，并称列名已给公司造成严重的经济与声誉损害。国防部6月10日刊于《联邦公报》的列名通知称，诺禾致源被认定由中国国务院国有资产监督管理委员会间接持有、并与中国工业和信息化部及中国人民解放军间接关联；通知援引的法律依据是2021财年《国防授权法》第1260H条，通知并未称该公司生产军事装备。
诺禾致源在6月18日的声明中否认上述认定，称公司是独立的上市公司、不存在国有控股与军方关联，已联系美国当局寻求移出清单，并称公司不设计、开发或销售军事产品。这些说法尚待法庭检验。诉状还提到，该公司在加州 Sacramento 与俄勒冈州 Beaverton 的设施约有180名美国员工。
按第1260H条，国防部须每年公布在美国运营的「中国军事企业」名单；自2026年6月30日起，国防部不得直接与名单企业签约，涉及名单企业产品与服务的更广采购限制将自2027年6月30日起生效。此类诉讼已有先例：今年8月18日，哥伦比亚特区联邦巡回上诉法院在禾赛科技诉国防部案中认定，列名带来的声誉与签约后果触发正当程序保障，企业有权在列名前获知非保密证据并获得有意义的回应机会；该判决对本案所在巡回区具有约束力，但不是对诺禾致源案的裁决。法院尚未就列名是否合法作出决定。
China's Novogene Sues the Pentagon Over 'Chinese Military Company' Listing
Washington — Chinese genomics company Novogene Co., Ltd. (Shanghai Stock Exchange STAR Market: 688315) and its U.S. subsidiary sued the U.S. Department of Defense on November 3 in the U.S. District Court for the District of Columbia, challenging the Pentagon's June decision to place the company on its 'Chinese military companies' list and asking the court to strike the designation.
The complaint alleges that the designation rested on inadequate evidence, was made without prior notice or a chance to respond, and violates the Administrative Procedure Act and the Fifth Amendment's due process guarantee; it says the listing has caused serious economic and reputational injury. In its designation notice published in the Federal Register on June 10, the Defense Department said Novogene was indirectly owned by China's State-owned Assets Supervision and Administration Commission of the State Council and indirectly affiliated with the Ministry of Industry and Information Technology and the People's Liberation Army. The notice cited Section 1260H of the fiscal 2021 National Defense Authorization Act; it did not say Novogene manufactured military equipment.
In a June 18 statement, Novogene denied those findings, calling itself an independent publicly listed enterprise with no state ownership or military affiliations, saying it had contacted U.S. authorities to seek removal, and stating that it does not design, develop or market military products. Those claims remain untested by the court. The complaint also cites about 180 U.S. employees at the company's facilities in Sacramento, California, and Beaverton, Oregon.
Under Section 1260H, the Pentagon must publish an annual list of qualifying entities operating in the United States. Since June 30, 2026, the department has been barred from contracting directly with listed companies, and broader restrictions on contracts covering their goods and services begin on June 30, 2027. There is precedent for such suits: on August 18, the U.S. Court of Appeals for the District of Columbia Circuit held in Hesai Technology's case that the reputational and contracting consequences of a listing engage due process, so a company must receive notice of the unclassified evidence and a meaningful chance to respond before designation. That ruling binds courts in the circuit but is not a decision in Novogene's case, which remains pending.
来源：路透社
发布：GSM·美国（发布链接）
图片来源：图：位于华盛顿的 E. Barrett Prettyman 美国法院大楼，美国哥伦比亚特区联邦地区法院设于此。照片：AgnosticPreachersKid，CC BY-SA 3.0，经 Wikimedia Commons。 / Photo: The E. Barrett Prettyman U.S. Courthouse in Washington, home to the U.S. District Court for the District of Columbia. Photo by AgnosticPreachersKid, CC BY-SA 3.0, via Wikimedia Commons.
GSM Global · 本篇英文版 English edition of this story
